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Abstract
Background: Histone deacetylase inhibitors (HDACi) are a new class of promising anti-tumour
agent inhibiting cell proliferation and survival in tumour cells with very low toxicity toward normal
cells. Neuroblastoma (NB) is the second most common solid tumour in children still associated
with poor outcome in higher stages and, thus NB strongly requires novel treatment modalities.
Results: We show here that the HDACi Sodium Butyrate (NaB), suberoylanilide hydroxamic acid
(SAHA) and Trichostatin A (TSA) strongly reduce NB cells viability. The anti-tumour activity of
these HDACi involved the induction of cell cycle arrest in the G2/M phase, followed by the
activation of the intrinsic apoptotic pathway, via the activation of the caspases cascade. Moreover,
HDACi mediated the activation of the pro-apoptotic proteins Bid and BimEL and the inactivation of
the anti-apoptotic proteins XIAP, Bcl-xL, RIP and survivin, that further enhanced the apoptotic
signal. Interestingly, the activity of these apoptosis regulators was modulated by several different
mechanisms, either by caspases dependent proteolytic cleavage or by degradation via the
proteasome pathway. In addition, HDACi strongly impaired the hypoxia-induced secretion of
VEGF by NB cells.
Conclusion: HDACi are therefore interesting new anti-tumour agents for targeting highly
malignant tumours such as NB, as these agents display a strong toxicity toward aggressive NB cells
and they may possibly reduce angiogenesis by decreasing VEGF production by NB cells.
Background
Histone deacetylase inhibitors (HDACi) are promising
new anti-tumour agents due to their low toxicity toward
normal cells and their ability to inhibit tumour growth in
vivo. HDACi are currently under clinical trials and have
activity in hematologic malignancies and solid tumours at
doses that are well tolerated by patients [1-3].
HDACs regulate the expression and the activity of many
proteins involved in cancer initiation and progression.
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Molecular Cancer 2008, 7:55 http://www.molecular-cancer.com/content/7/1/55HDACs affect gene expression by deacetylation of his-
tones and transcription factors, and also deacetylate
numerous other cellular proteins involved in cell growth,
cell migration, apoptosis and differentiation [2,4,5]. Thus
HDACi mediate their anti-tumour action by transcription-
dependent and transcription-independent mechanisms.
HDACi induce diverse responses in tumour cells, such as
differentiation, cell cycle arrest, cell death by the activa-
tion of the intrinsic apoptotic pathway, the extrinsic apop-
totic pathway, autophagic cell death, mitotic failure,
senescence, and ROS facilitated cell death in tumour cells
[2,5,6]. In addition, several HDACi affect tumour progres-
sion by their activities on angiogenesis and metastasis
[4,5,7]. Indeed, some HDACi were shown to inhibit ang-
iogenesis in vitro and in vivo, and to reduce the expression
of pro-angiogenesis factors such as HIF-1α and VEGF
[8,9]. Particular response to HDACi vary with tumour cell
type, the HDACi used, and the treatment modalities [3].
For example, cell cycle arrest was described to occur in G1/
S or in G2/M depending on the tumour cell types studied
[5,10,11].
Neuroblastoma is the most common solid extracranial
tumour in children and cause 15% of death from neopla-
sia in children [12,13]. Therefore, there is an urgent clini-
cal need for new therapeutic strategies, with improved
therapeutic potential. Several reports have described the
ability of HDACi such as CBHA, PB or BL1521 to induce
cell cycle arrest in G1/S phase and caspase-dependent
apoptosis in some NB cell lines [14-18]. The release of Bax
from Ku70 following acetylation of Ku70 was shown to
mediate HDACi-induced apoptosis in NB cells [17]. Some
studies have reported a reduction of NB tumour growth in
vivo either on HDACi treatment alone or in combination
with other treatment modalities [16,19-22]. We have pre-
viously reported that subtoxic doses of HDACi sensitised
NB cells to TRAIL-induced cell death by a caspases-
dependent increase in the pro- to anti-apoptotic proteins
ratio [23].
The present study dissects the detailed mechanisms of
HDACi anti-tumour activity in NB cells, that revealed to
be similar in both the S-type and N-type NB cells, in con-
trast to the chemotherapeutic drug Doxorubicin [24]. The
three HDACi, sodium butyrate (NaB), Trichostatin A
(TSA) and suberoylanilide hydroxamic acid (SAHA)
induced a cell cycle arrest in G2/M phase, followed by
induction of the intrinsic apoptotic pathway, via the acti-
vation of the caspases cascade. Interestingly, HDACi
increased the ratio between pro- to anti-apoptotic pro-
teins by different mechanisms, either by caspases depend-
ent cleavage or by degradation via the proteasome
pathway. In addition, hypoxia-mediated VEGF secretion
by NB cells was reduced by HDACi.
Results
NaB, SAHA, and TSA induce cell cycle arrest in G2/M 
phases in NB cells
The anti-tumour activity of three HDACi, NaB, SAHA, and
TSA was first analysed in various S-type and N-type NB
cells. We observed that these HDACi reduced NB cell via-
bility in a dose-dependent manner (Fig. 1A). While SH-EP
cells were the less sensitive NB cells, no significant differ-
ences in the sensitivity to HDACi could be observed
between S-type and N-type cells or between MYCN ampli-
fied compared to MYCN single-copy cells (Table 1).
As HDACi are known to affect both cell survival and cell
cycle progression, the effect of NaB, SAHA and TSA on cell
cycle progression in NB cells was then measured in SH-EP,
IMR32, LAN-1 and IGR-N91 cells. After 16 h of treatment,
HDACi induced an accumulation of cells with 4n DNA
content indicating a G2/M cell cycle arrest (Fig. 1B, and
data not shown). In addition, the number of cells in S-
phase was reduced following HDACi treatments (Fig. 1B).
Cell cycle arrest was not inhibited by the addition of the
pan-caspase inhibitor zVAD as illustrated with SH-EP cells
(Fig. 1b). Thus, NaB, SAHA and TSA induce a caspases
independent cell cycle arrest in G2/M phase in both S- and
N-type NB cells.
HDACi induce caspases-dependent cell death
HDACi-mediated apoptosis induction was then investi-
gated by the propidium iodide staining method in SH-EP,
LAN-1 and IMR32 cells. The percentage of sub-G1 popu-
lation of cells corresponding to apoptotic cells increased
over time between 24 h to 48 h (Fig. 2A and 2B). Apop-
totic cell death induced by HDACi was completely pro-
tected by the pan-caspases inhibitor zVAD (Fig. 2C).
These data indicate that HDACi induce caspases-depend-
ent cell death in both S- and N-type NB cells, and apopto-
sis occurs following cell cycle arrest in G2/M phase.
HDACi activate the intrinsic apoptotic pathway
To analyse if HDACi induce apoptosis by activating the
mitochondrial pathway, we measured the disruption of
the transmembrane mitochondrial potential (ΔΨm) (Fig.
3A). Treatment of SH-EP, LAN-1 and IMR32 cells either
with NaB, SAHA or TSA induced a strong reduction of the
ΔΨm in 60% to 80% of these cells after 48 h of treatment.
Time-course experiments showed that the disruption of
the ΔΨm was enhanced between 24 h to 48 h (Fig. 3B),
which correlates with the timing of apoptosis induction
observed in figure 2A and 2B. The depolarisation of the
membrane is partially caspases dependent, as zVAD mod-
erately protects from reduction of the ΔΨm (data not
shown). These results indicate that HDACi induce the
activation of the intrinsic apoptotic pathway in NB cells.Page 2 of 12
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NaB, SAHA, and TSA induce cell cycle arrest in G2/M phases in NB cellsFigure 1
NaB, SAHA, and TSA induce cell cycle arrest in G2/M phases in NB cells. A. S-type and N-type NB cell lines were 
treated with increasing doses of NaB, SAHA or TSA as indicated for 48 h. Cell viability was measured by MTS/PMS cell prolif-
eration assays. Mean values of three independent experiments are shown. MYCN non amplified (n.a.) and MYCN amplified (a.) 
cells are indicated. B. Cell cycle arrest was detected by the propidium staining method after stimulation for 16 h with 10 mM of 
NaB, 2.5 μM of SAHA or 1.5 μM of TSA for IMR32 cells, and with 20 mM of NaB, 20 μM of SAHA or 5 μM of TSA in the pres-
ence (+) or absence (-) of zVAD-fmk for SH-EP cells. Percentage of cells in G1, S, G2, and sub-G1 phases are indicated.
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As apoptosis induced by HDACi was protected by zVAD,
this suggests that HDACi activate the caspases cascade.
Indeed, immunoblotting analyses revealed that NaB,
SAHA and TSA induce the reduction of procaspases-2, -3
and -7 in SH-EP and IMR32 cells after 48 h of treatment,
while procaspase-9 was unaffected (Fig. 4A). As apoptosis
was shown to be dependent of caspases activity (Fig. 2C),
the reduction of pro-caspases induced by HDACi is due to
their activation by proteolytic cleavage rather than other
down-regulation mechanisms. Time-course analysis of
caspases cleavage indicated that it occurred between 16 h
to 30 h (data not shown). To confirm the caspases activa-
tion mediated by HDACi, we measured caspase-3-like
activity in SH-EP and IMR32 cells using the DEVD-pNA
substrate. Caspase-3-like activity was induced in cells
treated with NaB, SAHA, and TSA (Fig. 4B), indicating that
these HDACi induce caspases activation in both S- and N-
type NB cells.
HDACi inactivate anti-apoptotic proteins by distinct 
mechanisms
We have previously shown that subtoxic doses of HDACi
in combination with TRAIL induced the inactivation of
the anti-apoptotic proteins RIP, XIAP, Bcl-xL, and survivin,
as well as the activation of Bid and BimEL in a caspases
dependent manner [23]. To analyse if toxic doses of
HDACi induce similar effects, the expression level of these
proteins were then investigated by immunoblotting. NaB
and SAHA induced the reduction of the steady state level
of the anti-apoptotic proteins XIAP, Bcl-xL, RIP, and sur-
vivin, and that of the pro-apoptotic proteins Bid and
BimEL, as observed in SH-EP cells (Fig. 5A) and in IMR32
cells (Fig. 5A and data not shown). These effects were
observed between 16 h to 30 h of treatments (data not
shown) and all except survivin were caspases-dependent
as they were protected by the addition of zVAD (Fig. 5A).
Indeed, zVAD did not protect the HDACi-mediated
decrease in survivin expression, but on the opposite fur-
ther enhanced survivin downregulation (Fig. 5A). TSA
induced the same effect on XIAP, RIP, and survivin as NaB
and SAHA. In contrast, Bid and Bcl-xL were not affected by
TSA and the reduction of BimEL was not protected by
zVAD following TSA treatment.
We next investigated whether the reduction in survivin
expression level mediated by HDACi results from its deg-
radation by the proteasome using the proteasome inhibi-
tor Lactacystin. Results shown in figure 5B indicate that
Lactacystin strongly protected from a HDACi-mediated
survivin down-regulation. This indicates that in NB cells,
HDACi induce proteasome-mediated degradation of sur-
vivin, rather than caspases-dependent cleavage, as previ-
ously observed in co-treatment with subtoxic doses of
HDACi and TRAIL [23].
HDACi reduce hypoxia-induced secretion of VEGF
Certain HDACi mediate their anti-tumour activity by act-
ing on cell cycle progression and survival, but also by
affecting tumour angiogenesis via the reduction of HIF-1
and VEGF expression [4,5]. As NB are know to express
high level of VEGF, we investigated whether NaB, SAHA
and TSA had an effect on VEGF expression in NB cells.
Results of ELISA assay show that the amount of secreted
VEGF was strongly increased by hypoxia. Interestingly,
NaB, SAHA and TSA significantly reduced hypoxia-medi-
ated increase of VEGF secretion in both S-type (SH-EP)
and N-type (LAN-1 and IMR32) NB cells (Fig. 6).
Discussion
We have analysed in details the mechanisms of the antitu-
moral effect of the HDACi NaB, SAHA and TSA on human
NB cells. All cell lines analysed were strongly sensitive to
NaB (at mM concentration), or to SAHA and TSA (at
microM concentration), as previously described for other
tumour types [2]. With the exception of SH-EP cells,
which were the less sensitive cells, all other cell lines dis-
played a similar sensitivity to the HDACi. Thus, no corre-
lation could be found between the NMYC status, or the S-
type versus N-type of the cells, and their sensitivity to
HDACi. This is in agreement with a previous work report-
ing that the HDACi BL1521, TSA, and 4BP displayed a
similar toxicity toward NMYC amplified and unamplified
cells [25]. In contrast, other reports indicated that S-type
Table 1: The sensitivity of NB cell lines to NaB, SAHA and TSA is independent of MYCN and p53 status.
cell line IC50 NaB (mM) IC50 SAHA (uM) IC50 TSA (uM) MYCN status p53
SH-EP 11.1 ± 2.5 6.3 ± 3.0 1.3 ± 0.9 s.c. wt
CA2E 5.9 ± 1.5 4.5 ± 3.0 0.4 ± 0.1 A N.D.
SK-N-AS 13 ± 2.9 2.3 ± 0.3 0.3 ± 0.2 s.c. mt[45],[46]
LAN-1 3.3 ± 1.1 1.4 ± 0.3 0.3 ± 0.2 A mt[47]
IMR32 4.0 ± 1.4 2.5 ± 1.8 0.3 ± 0.2 A wt[47]
SH-SY-5Y 5.0 ± 2.8 1.6 ± 0.6 0.4 ± 0.1 s.c. wt
IGRN-91 3.8 ± 1.0 1.6 ± 0.4 0.7 ± 0.45 A mt[48]
IGRN-B8 14.4 ± 2.2 3.9 ± 0.2 0.5 ± 0.1 A mt[46]
s.c., single copy; A, amplified; wt, wild type; mt, mutated; N.D., not describedPage 4 of 12
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Caspases-dependent apoptosis is mediated by HDACiFigure 2
Caspases-dependent apoptosis is mediated by HDACi. Time-course analyses of HDACi-induced apoptosis in SH-EP 
cells (A), in IMR32 and LAN-1 cells (B). Cells were treated with indicated doses of NaB (mM), SAHA (μM) or TSA (μM). C. 
The caspases inhibitor zVAD completely prevents HDACi-induced apoptosis. SH-EP and IMR32 cells were treated for 24 h 
with NaB, SAHA, or TSA, in the presence (white) or in the absence (black) of zVAD. Percentage of sub-G1 apoptotic cells 
detected by the propidium staining method after stimulation with HDACi are indicated in the histograms (A), or as bare graph 
(B and C).
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that the NMYC amplified SMS-KCNR cells were more sen-
sitive to MS-27-275 than the unamplified SK-N-AS cells
[20]. In addition, in contrast to a very recent report show-
ing that p53 is involved in the sensitivity of SH-SY5Y and
SK-N-BE NB cell lines to VPA and Butyrate, we did not
find any correlation between p53 status and NB cell lines
sensitivity to NaB, SAHA and TSA (Table 1). These con-
flicting results may be explained by the fact that certain
HDACi may exert their antitumoral activity by distinct
mechanisms, as they selectively inhibit different HDACs
[5,27]. Indeed, we have observed that TSA differently
affected several pro- and anti-apoptotic proteins com-
pared to NaB and SAHA.
Among the HDACi-activated antitumoral actions, cell
cycle arrest has been described in many type of tumours
[5,10,11], as well as in NB [15,16,18]. In contrast to a pre-
vious study indicating that the HDACI BL1521 induced
cell cycle arrest in G1 phase in SK-N-AS and IMR32 cells
[15], we have shown here that NaB, SAHA and TSA induce
cell cycle arrest in the G2-M phase in both S-type and N-
type NB cells. This is in accordance with a very recent
report showing that Butyrate and VPA induce cell cycle
arrest in the G2/M phase [28]. The cell cycle arrest induced
by HDACi was observed around 16 h, preceding apopto-
sis induction, which occurs from 24 to 48 h. The cyclin-
dependent kinase inhibitor p21 (WAF1/CIP1) is one of
the most common target genes of different HDACi, and
was reported to be largely associated with cell cycle arrest
in G1 and G2 phases [5]. As previously described in NB
cells [18,28], we also observed the overexpression of p21
(WAF1/CIP1) following treatment with NaB, SAHA and
TSA (data not shown), thus p21 overexpression may play
a role in the observed G2/M cell cycle arrest. In contrast,
the cell cycle arrest was independent on p53, as several NB
cells analysed express mutated p53 protein (Table 1).
We have shown here that NaB, SAHA and TSA induced
caspases dependent apoptosis by the activation of the
intrinsic apoptotic pathway in NB cells, as previously
described in different tumours [10,11], and in NB cells for
several HDACi [16,29]. In contrast, the involvement of
TRAIL and the TRAIL-receptor pathway in HDACi-
induced apoptosis was shown to vary depending on
tumour cell types [30]. Our results demonstrated that in
NB cell lines, apoptosis induced by NaB, SAHA and TSA
did not required a functional death receptor pathway.
Indeed, the N-type NB cell lines, that are deficient in the
initiator caspases-8 and -10, displayed a sensitivity to
HDACi similar to that of S-type NB cells expressing these
caspases. In addition, the cell surface expression level of
TRAIL and TRAIL-receptor was not increased by HDACi
[23], and SH-EP cells overexpressing FLIP [31] displayed
similar sensitivity to HDACi than control cells (data not
shown). Altogether these findings indicate that the death
receptor pathway is not involved in HDACi-induced
apoptosis in NB cells, despite the fact that sub-toxic doses
of HDACi can sensitise NB cells to TRAIL-mediated apop-
tosis [23]. Interestingly, no difference in the mechanisms
of antitumoral response induced by HDACi could be
observed between S-type and N-type NB cell lines. This is
in contrast to the cytotoxic effect of Doxorubicin, which
induced caspases-dependent cell death in S-type NB cells
and caspases-independent cell death in N-type NB cells
[24].
In this study we have further analysed in details the mech-
anisms of apoptosis induction by NaB, SAHA and TSA.
The three HDACi increased the ratio between pro- and
anti-apoptotic proteins. While NaB and SAHA mediated
the downregulation of RIP, XIAP, Bcl-xL and survivin, and
Activation of the mitochondrial signalling pathwayFigure 3
Activation of the mitochondrial signalling pathway. A. 
SH-EP, LAN-1, and IMR32 cells were untreated (no) or 
treated with NaB, SAHA or TSA for 48 h as indicated in Fig. 
2A and 2B. B. SH-EP cells were treated with NaB, SAHA or 
TSA (as in Fig. 2A) for 16, 24, or 48 h. The loss of ΔΨm was 
measured by flow cytometry using the fluorescent dye JC-1. 
The percentage of cells with low ΔΨm is indicated. Mean of 
two independent experiments are indicated in B.Page 6 of 12
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Molecular Cancer 2008, 7:55 http://www.molecular-cancer.com/content/7/1/55the activation of Bid and BimEL, TSA only induced the
downregulation of XIAP, RIP and survivin. Thus, different
HDACi may act through distinct mechanisms to induce
their antitumoral response in the same tumour cell type.
NaB and SAHA induced the caspases-dependent activa-
tion of Bid, as Bid reduction was protected by the pan-cas-
pase inhibitor zVAD, which also occurs in N-type NB cells
in absence of caspases-8 and -10 expression. This suggests
HDACi activate the caspases cascadeFigure 4
HDACi activate the caspases cascade. A. Cells were untreated (no) or treated with 20 mM NaB, 20 μM SAHA or 5 μM 
TSA for SH-EP, or with 10 mM of NaB, 2.5 μM of SAHA or 1.5 μM of TSA for IMR32 during 48 h. Whole cell extracts were 
analysed by immunoblotting for the cleavage of caspases-2, -3, -7 and -9. β-actin was used as loading control. B. Caspase-3-like 
activities are induced by HDACi. Hydrolysis of DEVD-pNA was measured in SH-EP or IMR32 cells unstimulated (no) or stim-
ulated with NaB (mM), SAHA (μM), or TSA (μM) for 48 h as indicated. The caspase-3-like activities of stimulated cells, relative 
to unstimulated cells are indicated.
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Molecular Cancer 2008, 7:55 http://www.molecular-cancer.com/content/7/1/55that the activation of the intrinsic pathway proceeds via an
amplification loop that is independent of caspases-8 and
-10, but dependent of other caspases as disruption of the
ΔΨm was partially protected by zVAD (data not shown).
Bid was indeed reported to be the substrate of other cas-
pases, such as caspase-2 or caspase-3 [32].
HDACi increase the pro- to anti-apoptotic protein ratio by different mechanismsFigure 5
HDACi increase the pro- to anti-apoptotic protein ratio by different mechanisms. A. SH-EP cells were unstimu-
lated (no), or stimulated with NaB (20 mM), SAHA (20 μM) or TSA (5 μM) in the absence (-) or in the presence (+) of zVAD-
fmk for 48 h. IMR32 cells were unstimulated (no) or stimulated with 2.5 μM of SAHA in the absence (-) or in the presence (+) 
of zVAD-fmk for 48 h. Whole cell extracts were analysed by immunoblotting with anti-Bid, Bim, XIAP, RIP, Bcl-xL survivin anti-
bodies. B. SH-EP cells were unstimulated (no), or stimulated with NaB, SAHA or TSA in the absence (-) or in the presence (+) 
of Lactacystin (10 μM) as in (A). IMR32 were unstimulated (no) or stimulated with SAHA (5 μM) in the absence (-) or in the 
presence (+) of Lactacystin (10 μM) for 48 h. Whole cell extracts were analysed for the presence of survivin. β-actin was used 
as loading control (A and B).
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Molecular Cancer 2008, 7:55 http://www.molecular-cancer.com/content/7/1/55The activation of BimEL by caspase-3 was previously
shown to induce a positive amplification loop by increas-
ing the affinity of BimEL to Bcl-2 [33]. Thus, BimEL may be
activated by caspases-dependent cleavage by NaB and
SAHA in NB cells, as previously observed by co-treatment
with subtoxic doses of HDACi and TRAIL [23].
Interestingly, we have observed that the down-regulation
of the anti-apoptotic proteins RIP, XIAP, Bcl-xL and sur-
vivin occurred by different mechanisms, either by cas-
pases dependent cleavage or by degradation via the
proteasome pathway. Indeed, in contrast to RIP, XIAP,
and Bclx, the downregulation of survivin was not pro-
tected by the caspases inhibitor zVAD, which strikingly
further increased survivin downregulation. In normal
cells, survivin is expressed in a cell cycle-dependent man-
ner, with an increased expression during the G2/M phase
in normal cells [34] and survivin degradation is tightly
regulated via the ubiquitin-proteasome pathway in a cell
cycle dependent manner [35]. In tumour cells in contrast,
survivin expression is globally deregulated and is overex-
pressed in all cell-cycle phases [36]. Thus, our observation
that HDACi-mediated downregulation of survivin in NB
cells despite G2/M phase cell cycle arrest was not surpris-
ing. Survivin downregulation was prevented by the pro-
teasome inhibitor Lactacystin, indicating that NaB, SAHA
and TSA mediated survivin degradation via the ubiquitin-
proteasome pathway. This is in accordance with previous
reports describing that the downregulation of survivin
occurred via the proteasome pathway after induction with
the HDACi chlamydocin in ovarian carcicoma cells [37]
and with valproic acid in colon cancer [38]. Interestingly,
the downregulation of survivin induced by subtoxic doses
of HDACi in combination with TRAIL occurred by cas-
pases-dependent cleavages [23]. Thus, the mechanisms of
HDACi-mediated apoptosis may vary in the same cell
lines depending on the doses or the addition of combined
treatment. We have shown previously that the downregu-
lation of survivin expression by siRNA sensitised NB cells
to HDACi [23]. This suggests that part of the antitumoral
effect of HDACi in NB cells may be due to the downregu-
lation of survivin via the proteasome pathway.
In addition to the role of HDACi in reducing tumour ini-
tiation by their effects on cell proliferation and survival,
HDACi were found to repress angiogenesis in vitro and in
vivo, and to reduce the expression of pro-angiogenic fac-
tors, such as HIF and VEGF [5,8,9]. VEGF is a key regulator
of angiogenesis, by inducing endothelial cell proliferation
and migration [39]. Most NB cell lines and tumours
express VEGF, and VEGF expression level correlates with
tumour progression and poor prognostic [40,41]. Moreo-
ver, blockade of VEGF function was shown to be associ-
ated with suppression of NB growth [42,43]. We have
shown here that NaB, SAHA and TSA strongly decrease the
HDACi repress hypoxia induced VEGF expressionFigure 6
HDACi repress hypoxia induced VEGF expression. 
SH-EP cells were stimulated with NaB (20 mM), SAHA (20 
μM) or TSA (5 μM), LAN-1 and IMR32 cells were stimulated 
with NaB (10 mM), SAHA (5 μM) or TSA (1.5 μM), or 
unstimulated (no) for 24 h under normoxia or hypoxia (1% 
O2). The bare graphs represent the amount of secreted 
VEGF in the supernatant normalized by the total amount of 
protein obtained in the corresponding cell lysate. Mean of 
duplicates of a representative experiment are indicated.
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Molecular Cancer 2008, 7:55 http://www.molecular-cancer.com/content/7/1/55hypoxia-mediated induction of VEGF secretion in both S-
type and N-type NB cells. This suggests that NaB, SAHA
and TSA may be efficient to reduce NB growth in vivo by
decreasing tumour angiogenesis in addition to tumour
cell growth and survival. Indeed, HDACi-mediated reduc-
tion of VEGF expression by 4-phenylbutyrate, or decrease
of tumour vasculature by MS-27-275 have been previ-
ously described in NB tumour xenograft model [16,20].
Conclusion
By dissecting the molecular pathways involved in the
HDACi-mediated toxicity in NB cells, we have identified
the participation of a complex array of distinct mecha-
nisms, that outline the complexity of the HDACi-medi-
ated effects. In addition to the observation that NaB,
SAHA and TSA are potent therapeutic agents against
highly malignant NB cells, by affecting both cell cycle pro-
gression and survival, our study also underlines a possible
antiangiogenic action of HDACi in NB. The effect of
HDACi on VEGF production thus supports HDACi anti-
tumour activity reported in human NB xenograft models
[19,20] and suggests a role for the microenvironment,
that should be rapidly addressed in vivo. Altogether, our
and others observations confirm the interest in HDACi as
promising new treatment modalities for patients with
recurrent high-risk neuroblastoma.
Methods
Cell culture and reagents
The S-type NB cells SH-EP, CA2E, and SK-N-AS and the N-
type NB cells LAN-1, IMR32, SH-SY-5Y, IGRN-91, IGRN-
B8 were grown in DMEM medium supplemented with 2
mM L-glutamine, 100 U/ml Penicillin, 0.1 mg/ml strepto-
mycin, and 10% of FCS. Sodium butyrate (Fluka) was dis-
solved in H2O and stored at -20°C. SAHA (Biovision) and
TSA (Sigma) were dissolved in DMSO and store at -20°C.
Cells were treated with the caspases inhibitor zVAD-fmk
(100 μM, Bachem) or with Lactacystin (10 μM, Alexis Cor-
poration) when indicated.
Cell viability assays
Cells (1–2.5*104/well in 96-well-plates; 100 μl) were
plated 24 h before treatment and incubated with HDACi
for 48 h. Assays were performed in quadruplicates. Viabil-
ity was measured using the MTS/PMS cell proliferation kit
from Promega according to manufacturer's instructions.
Percentage of cell viability as compared to untreated con-
trols was calculated.
Apoptosis and cell cycle analyses by the propidium iodide 
staining method
Cells were washed twice with ice-cold PBS, resuspended in
1 ml of ice-cold PBS, and fixed with 3 ml of 100% ice-cold
ethanol for 1 h at 4°C. For staining with propidium
iodide (PI), cells were washed twice in ice-cold PBS, resus-
pended in 0.2 ml of PBS containing 200 μg/ml RNaseA
and 10 μg/ml propidium iodide and incubated for 30 min
at room temperature. The stained cells were analyzed
using a FACScan flow cytometer (Becton Dickinson).
Immunoblotting
Whole cell extracts were prepared as already described
[44]. Protein extracts (50 μg) were loaded on 12% SDS-
PAGE and transferred on nitrocellulose membranes. Blots
were saturated with 5% skim milk, 0.1% Tween 20 in TBS
and revealed using mouse monoclonal antibodies to
detect caspase-2 (Apotech Corporation), caspase-3, cas-
pase-7, RIP, XIAP (BD Transduction Laboratories), and β-
actin (Sigma). Polyclonal rabbit antibodies were used to
detect caspase-9 (Cell Signaling), Bid, Bcl-xL (BD Trans-
duction Laboratories), Bim (Imgenex), and survivin (R&D
systems). Binding of the first antibody was revealed by
incubation with either goat anti-mouse IgG-HRP (Jackson
ImmunoResearch) or goat anti-rabbit IgG-HRP (Nordic
Immunological Laboratories). Bound antibodies were
detected using the Lumi-light western blotting substrate
(Roche) according manufacturer's instructions.
Caspases activities
Caspase-3 like activities were measured using the cas-
pases-3 colorimetric protease assay kit from MBL.
Cytosolic lysates were prepared after HDACi treatments
according to manufacturer instructions. Two hundred μg
of protein extracts were incubated with 200 μM of DEVD-
pNA colorimetric substrate for 3 h at 37°C. Cell lysates
were incubated with 10 μM of caspase inhibitor (zDEVD-
fmk) for 30 min before addition of caspase substrate to
control the specificity of caspase-3 like activation. Hydro-
lysed pNA was detected using a microtiter plate reader at
405 nm. Background absorbance from cell lysates and
buffers were subtracted from the absorbance of stimulated
and unstimulated samples before calculation of relative
caspases activities.
Analysis of mitochondrial transmembrane potential
The disruption of mitochondrial membrane potential
ΔΨm was analysed by staining the cells with the fluores-
cent dye JC-1 (Calbiochem) according to manufacturer's
protocol. Loss of ΔΨm resulting in reduction of red aggre-
gates was measured by flow cytometry using the FL2 chan-
nel (550–650 nm) (FACScan, Becton Dickinson). Results
are given in percentage of cells with low ΔΨm compared
to untreated controls.
VEGF measurement
Cells (2.5*106 SH-EP. 3.5*106 LAN-1 and IMR32) were
platted in 75 cm2 dishes the day before induction. Cells
were treated with HDACi under normoxic condition or
under hypoxia (1% O2) for 24 h. Cell free supernatant
were collected and whole cell extracts were prepared byPage 10 of 12
(page number not for citation purposes)
Molecular Cancer 2008, 7:55 http://www.molecular-cancer.com/content/7/1/55incubating cell pellets in lysis buffer (50 mM Tris-HCl pH
7.4, 150 mM NaCl, 10 mM EDTA, 0.25% Triton X-100,
0.1% NP-40) supplemented protease inhibitor cocktail
tablets (complete mini, Roche) for 10 min in ice. Homoge-
nates were centrifuged 20 min. at 16'000 g and superna-
tant were collected. Protein concentration was measured
using the micro BCA protein assay kit (Pierce). Soluble
VEGF was measured in 50 μl of supernatants in duplicates
using the VEGF DuoSet ELISA kit (R&D system) according
to manufacturer's instructions.
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